Endobronchial Ultrasound Biopsy Market Size and Forecast 2025–2033

Introduction

The Endobronchial Ultrasound (EBUS) Biopsy market is gaining strong traction worldwide due to rising incidence of respiratory diseases, growth in lung cancer diagnosis, and increasing adoption of minimally invasive diagnostic procedures. EBUS biopsy technology provides a safer, faster, and more accurate alternative to traditional surgical biopsies, enabling clinicians to diagnose conditions such as lung cancer, tuberculosis, and other thoracic disorders with improved patient outcomes. Multiple market intelligence reports forecast significant expansion of this sector through 2033.


---

Market Size and Growth Outlook (2025–2033)

According to Grand View Research, the global endobronchial ultrasound biopsy market was valued at approximately USD 728.6 million in 2024 and is expected to grow steadily to reach around USD 1,186.5 million by 2033, expanding at a compound annual growth rate (CAGR) of about 6.3% between 2025 and 2033.

Another industry analysis from Strategic Revenue Insights estimates the market to expand from about USD 751.6 million in 2024 to nearly USD 1.25 billion by 2033, driven by rising disease burden and improved diagnostic adoption, with a CAGR around 5.8%.

These forecasts reflect consistent long-term growth expectations, with the market expected to nearly double in value over the forecast period.


---

Key Drivers of Market Growth

The growth of the endobronchial ultrasound biopsy market is supported by multiple factors:

1. Rising Prevalence of Respiratory Diseases

Chronic respiratory conditions and lung cancer remain among the top causes of morbidity and mortality globally. With increasing tobacco use, air pollution, and aging populations in key regions, the demand for reliable, early diagnostic tools like EBUS biopsy continues to rise.


---

2. Shift toward Minimally Invasive Procedures

EBUS biopsy is gaining preference over traditional surgical methods due to lower patient risk, shorter recovery times, and higher diagnostic accuracy. These clinical advantages are encouraging broader adoption among pulmonologists and oncology specialists.


---

3. Technological Advancements in EBUS Devices

Ongoing innovation in ultrasound imaging quality, needle design, and device navigation systems is expanding the clinical utility of EBUS biopsy procedures. Improved visualization tools enhance the accuracy of mediastinal and peripheral lung tissue sampling.


---

Market Segmentation

By Product

The EBUS device category, including ultrasound scopes and related biopsy instruments, commands a significant share of market revenue. EBUS scopes remain the largest revenue generators, reflecting their central role in guided biopsy procedures.


---

By Procedure

Among procedures, EBUS-transbronchial needle aspiration (EBUS-TBNA) dominates due to its extensive use in mediastinal lymph node staging in lung cancer patients. Adoption rates for EBUS-TBNA continue to increase as clinicians prioritize minimally invasive diagnostics.


---

By End Use

Hospitals represent the largest end-use application segment, accounting for more than half of the market share. This is driven by the presence of advanced oncology and pulmonary units capable of performing EBUS biopsy procedures. Specialty centers and diagnostic clinics are also expanding adoption as access to technology spreads globally.


---

Regional Insights

North America

North America continues to lead the global EBUS biopsy market, accounting for a significant portion of revenue. The strong prevalence of lung cancer, well-established healthcare infrastructure, and high adoption rates of minimally invasive procedures are key contributors to market dominance.


---

Europe

Europe holds a substantial share of the market, with countries like Germany, the United Kingdom, and France showing steady growth. Hospitals and specialty centers across the region are increasingly using EBUS technologies for accurate thoracic diagnostics.


---

Asia-Pacific

The Asia-Pacific region is emerging as a fast-growing market. China and Japan are key contributors, with investments in healthcare infrastructure and rising training among pulmonologists fuelling EBUS adoption. India and South Korea also show strong incremental growth potential.


---

Middle East & Africa

While currently representing a smaller portion of total revenue, the Middle East & Africa region is expanding its footprint as tertiary hospitals upgrade facilities and training in EBUS techniques grows.


---

Competitive Landscape

The EBUS biopsy market is highly competitive and includes several major global players:

GE Healthcare

Siemens Healthineers

Boston Scientific Corporation

Olympus Corporation

Cook Medical

FUJIFILM Holdings Corporation

Medi-Globe Technologies GmbH

Philips

ACE Medical Devices

Praxis Medical Devices


These companies are focusing on innovation, clinical partnerships, and expanded distribution networks to maintain and grow their market presence. Technological collaborations and new product developments remain critical competitive strategies.


---

Future Prospects and Challenges

Opportunities

Expanding indications: Growth in use of EBUS biopsy for a wider range of pulmonary and thoracic conditions.

Emerging markets: Increasing healthcare investments in Asia-Pacific and Middle East regions.

Training and awareness: Enhanced physician training programs to boost procedure adoption.



---

Challenges

High equipment costs: The cost of acquiring and maintaining EBUS systems can be a barrier in lower-income regions.

Skilled personnel shortage: Limited availability of trained specialists to perform EBUS procedures.

Regulatory hurdles: Market access challenges in some countries due to regulatory requirements.



---

Conclusion

The Endobronchial Ultrasound Biopsy market is poised for steady growth from 2025 to 2033, driven by technological advancements, rising disease burden, and wider clinical adoption of minimally invasive diagnostics. With projections ranging from USD 1.18–1.27 billion by 2033, this market represents a significant opportunity for healthcare providers, device manufacturers, and investors focusing on advanced pulmonary diagnostic solutions.